1Chi-Wei Chang, 2Wen-Sheng Huang, 3Tsung-Hsun Yu, 5Ching-Huang Lo, 3,4Skye Hsin-Hsien Yeh*
1 R&D department, Primo Biotechnology Co., Ltd., Taipei, Taiwan
2 Department of Nuclear Medicine, Chang Bing Show Chwan Memorial Hospital, Changhua, Taiwan
3 School of Medicine, National Defense Medical Center, Taipei, Taiwan
4 Brain Research Center, National Yang Ming Chaio Tung University, Taipei, Taiwan5 Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
This study poster was presented at 2024 Annual Conference of Society of Nuclear Medicine, Taiwan.
This study was designed to assess the potential of [18F]fluoroacetate([18F]FAC) as a PET imaging radiotracer applied to a pancreatic tumors in mouse model.
By using a Tracerlab MX synthesizer, the research team successfully synthesized a cGMP-level [18F]FAC at Shin-Kong Memorial Hospital, performing quality assurance testing to ensure its radiochemical purity and sterility. In vivo study results showed that compared to the traditionally used [18F]FDG, [18F]FAC could detect tumor xenografts two days earlier during the initial stage of tumor formation, although the visualization effect of [18F]FDG was more distinct in imaging. These findings confirmed not only the synthesis stability and radiochemical yield of [18F]FAC but also indicated its potential for exploring metabolic changes, making it suitable for long-term preclinical studies.